Connect with us

Press Release

Gene Kwon: Pay Closer Attention to People Than to Plans

Published

2 months ago

on

  • Gene Kwon, Salt Lake City entrepreneur and co-founder of eHub, explains why the right people matter more than the perfect strategy.

The Turnaround Nobody Planned For

Utah, USA, Jul 24, 2026, ZEX PR WIRE — A few years into building what looked like a solid business, a founder realized the strategy was working, but the company was not. Every plan was being executed. Every milestone was being hit. But the team felt disconnected. Decisions took too long. Trust was low. Growth had stalled.

The shift came when the founder stopped obsessing over the next tactical move and started paying attention to who was in the room. Within six months, the company had rebuilt its leadership team, clarified who owned what, and started moving faster than ever. The plan had not changed. The people had.

“Pay closer attention to people than to plans,” says Gene Kwon, co-founder of eHub and Ernst and Young Entrepreneur of the Year. “The right people can make an average idea successful. The wrong people can make a great idea fail.”

Lessons from the Court

Kwon grew up in Oregon and Utah and became a ranked junior tennis player. He later played collegiate tennis at the University of Washington, where he earned a degree in English. Tennis taught him something most business books skip over.

“Tennis teaches you accountability,” Kwon explains. “When you’re on the court, there’s nobody else to blame. You learn how to adjust and keep moving forward.”

That mindset carried into his career. After college, Kwon co-founded Move Method and later helped launch eHub, a logistics and shipping solutions company based in Salt Lake City. Along the way, he earned recognition including the Forty Under Forty Business Award and served on the board of the Package Shippers Association.

But awards do not tell the full story.

“It has been my failures that have taught me the most,” Kwon says, “enabling a unique perspective on business and in life. A perspective of humility, gratitude and integrity.”

Why Good Businesses Start with Real Problems

Kwon believes most companies fail because they solve the wrong problem or solve it for the wrong reason.

“I’ve always believed that good businesses start by helping people solve real problems,” he says. “If you stay focused on that, growth usually follows.”

At eHub, the problem was clear. Businesses were spending too much time and money trying to manage shipping. The solution was not another platform. It was a partner that could simplify operations and help companies move faster.

“There were businesses spending too much time and money trying to manage shipping,” Kwon says. “We wanted to create solutions that made operations easier and more efficient.”

The approach worked because it started with listening, not pitching.

Copy This Framework: The Five-Phase People-First Strategy

Kwon’s approach to building businesses is less about following a rigid plan and more about building the right team, asking better questions, and staying focused on what matters. Here is how to apply it.

Phase 1: Audit Your Current Team Before you hire or fire anyone, get honest about who you have. Who makes decisions faster? Who slows things down? Who do people trust? Write it down. You cannot fix what you will not name.

Phase 2: Define What You Actually Need Stop hiring based on job descriptions. Start hiring based on gaps. Do you need someone who can execute, or someone who can think three steps ahead? Do you need a builder or a manager? Be specific.

Phase 3: Prioritize Trust Over Talent Talent gets you in the door. Trust keeps you in the room. Kwon says companies only grow when people trust each other and work toward the same goals. If you cannot trust someone with bad news, you cannot trust them with your business.

Phase 4: Ask Better Questions “The challenge isn’t finding answers anymore,” Kwon says. “The challenge is asking better questions.” Stop asking what went wrong. Start asking what you missed. Stop asking how to grow faster. Start asking what is slowing you down.

Phase 5: Build Relationships That Outlast Transactions “One conversation can completely change your perspective,” Kwon notes. “You never know where a good relationship might lead.” Invest in people before you need something from them. The best opportunities come from relationships, not networking events.

Quick Wins You Can Implement This Week

  • Schedule a 15-minute one-on-one with every person on your core team. Ask one question: What is slowing you down right now?

  • Identify one decision that has been stuck for more than two weeks. Assign it to one person with full authority to move it forward.

  • Write down the names of three people you trust completely. Make sure at least one of them is involved in every major decision.

  • Replace one status meeting with a problem-solving session. Bring the right people. Ask better questions.

  • Reach out to one person you respect but have not spoken to in six months. No agenda. Just reconnect.

Red Flags That Signal You Are Focusing on the Wrong Things

  • You can recite your strategy but cannot name the last time your team felt aligned.

  • Meetings are getting longer, but decisions are not getting clearer.

  • You are hiring to fill roles instead of solve problems.

  • People are waiting for permission instead of taking ownership.

  • You have more plans than you have people who can execute them.

  • You are proud of your idea but frustrated with your team.

  • Growth has stalled, but you keep tweaking the plan instead of evaluating the people.

Why Curiosity Beats Ambition

Kwon has a contrarian view on what drives long-term success.

“I think ambition is overrated,” he says. “Ambition is useful because it gives you direction, but curiosity is what keeps you growing.”

Curiosity leads to better questions. Better questions lead to better decisions. Better decisions lead to better outcomes. And better outcomes come from better people.

“Having a second chance makes you want to work even harder,” Kwon reflects. That second-chance mindset has shaped how he builds companies, leads teams, and shows up every day.

Apply This Framework to Your Business This Week

If you are leading a company, a team, or a project, stop and ask yourself one question: Am I spending more time perfecting the plan or understanding the people?

This week, pick one phase from the framework above and put it into action. Have the hard conversation. Ask the better question. Rebuild trust where it has been lost. The right people will take an average plan and make it work. The wrong people will take a great plan and watch it fail.

The choice is yours. But the answer is always people first.

About Gene Kwon

Gene Kwon is a co-founder and partner at eHub, a logistics and shipping solutions company based in Salt Lake City, Utah. He also co-founded Move Method and has earned recognition including Ernst and Young Entrepreneur of the Year and the Forty Under Forty Business Award. A former collegiate tennis player at the University of Washington, Kwon serves on the board of the Package Shippers Association and continues to help businesses grow through innovation, leadership, and a people-first approach.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

RGMBS 2026 Life Sciences Innovation Forum Draws More Than USD 120 Million in Investor Interest as 23 Global Biotech Innovators Pitch in Riyadh

Published

11 hours ago

on

September 17, 2026

By

RIYADH, Saudi Arabia – The Life Sciences Innovation Forum (LSIF), the investment platform of the Riyadh Global Medical Biotechnology Summit (RGMBS 2026), brought 23 biotechnology companies from eight countries to Riyadh to pitch to investors, judges, and leaders of the Kingdom’s life sciences ecosystem.

Companies from eight countries pitched to investors across five scientific heats, with Saudi Arabia the second-largest market represented.

Dr Abdulaziz Alrifi, Director Of Partnerships, KAIMRC, stated, “We were proud to welcome leading investment firms that expressed their willingness to invest more than $USD 120 milliond in promising biotech opportunities emerging from LSIF 2026. The journey culminated with the announcement of the LSIF 2026 Grand Winner: Bilix from South Korea.”

On winning, a representative of Bilix enthused, “Winning LSIF 2026 is a great honor, however the real win is scaling our startup with the Kingdom’s research ecosystem”

Where RGMBS 2026 set out the scale of Saudi Arabia’s biotechnology ambition, LSIF put that ambition in front of the founders and investors who will shape the sector’s next decade. The United States led the cohort with eight companies, with Saudi Arabia second at four, followed by South Korea, the United Kingdom, Australia, France, Germany, and Switzerland. Several international companies presented pathways to localization, research, or clinical development in the Kingdom.

FIVE HEATS, ONE FRONTIER

Companies competed across five heats, each at the leading edge of life sciences innovation.

AI and Bio Data. Amprologix of the United Kingdom presented AI-assisted discovery of narrow-spectrum peptide antibiotics targeting drug-resistant pathogens. Pneumatica Bio of Australia combines mechanistic modelling, machine learning, and automated cell experiments to better predict human therapeutic response, while Saudi company LinusBio MENA presented precision exposomics built on hair-based biomarker profiling.

Vaccine Development and Biomanufacturing. Biotech Innovations Company of Saudi Arabia presented a recombinant-protein MERS-CoV vaccine program focused on regional biosecurity and local manufacturing. OctoCells of France presented an animal-free 3D bioscaffold platform designed to reduce the water, infrastructure, and manufacturing burden of producing biologics and cell therapies, and Cevza Therapeutics of Australia an RNA therapy platform with planned research and development localization in the Kingdom.

Cellular Therapy and Gene Editing. CellKure of the United States highlighted Phase 1 results for its multi-antigen T-cell therapy in acute myeloid leukemia. MVRIX of South Korea presented an in vivo CAR-T approach using targeted mRNA delivery, and Saudi company Medixcel a platform to bring cell and gene therapy capabilities, partnerships, and manufacturing into the Kingdom.

Bioengineering and Synthetic Biology. NanoZymeX of Switzerland presented a lipid nanoparticle platform to improve enzyme replacement therapy for lysosomal storage diseases, beginning with Pompe disease. AUREXO Therapeutics of the United States presented engineered bacterial vesicles for precision oncology, and Ingenskin Therapeutics of France an autologous skin substitute for chronic wounds, burns, and trauma.

Diagnostics and Drug Discovery. SiNON Nano Sciences of the United States presented a carbon nanoparticle platform designed to cross the blood-brain barrier. Spirea of the United Kingdom presented a dual-payload antibody-drug conjugate platform to address cancer drug resistance, and Accanito Therapeutics of the United States a clinical-stage oncology platform with a proposal for technology transfer and local manufacturing in Saudi Arabia.

Questions from judges and the audience concentrated on turning science into treatments: regulatory routes, clinical evidence, manufacturing scale-up, localization economics, and intellectual property. LSIF 2026 was sponsored by Chiyoda Corporation.

Alongside Grand Winner Bilix, four category awards were presented: the Most Scalable Biotech Startup Award to CellKure, the Outstanding Founding Team Award to Quantabia, the Breakthrough Science Award to Swaza, and the Innovation Excellence Award to Agemica.

LSIF 2026 took place as part of RGMBS 2026, held from 14 to 16 September in Riyadh. The Summit was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment, Invest Saudi, and the Saudi Data & AI Authority (SDAIA) serving as key strategic partners.

About The Riyadh Global Medical Biotechnology Summit

The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia’s flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom’s emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org

FOR FURTHER INFORMATION

Email: PR@legends.sa

Telephone: +966 559 810 777

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Riyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia’s Commitment to Lead the Future of Biotechnology

Published

11 hours ago

on

September 17, 2026

By

RIYADH, Saudi Arabia – The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia’s ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom’s leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place.

More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh.

The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony.

Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit’s work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love.

FOUR PILLARS, ONE NATIONAL MISSION

RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions.

  1. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom’s entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool.
  2. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom’s essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million.
  3. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities’ Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan’s Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative.
  4. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master’s programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon.

THREE DAYS ON THE MAIN STAGE

  1. Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR.
  2. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs.
  3. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony.

“RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope.

“Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families.”

H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS .

RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom’s place at the forefront of global biotechnology in the years ahead.

About The Riyadh Global Medical Biotechnology Summit

The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia’s flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom’s emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org

FOR FURTHER INFORMATION

Email: PR@legends.sa

Telephone: +966 559 810 777

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AtlasClear Holdings Reports Preliminary Fiscal 2026 Revenue of Approximately $20.1 Million, Up 85%; Revenue Plus Interest Income of Approximately $21.9 Million

Published

15 hours ago

on

September 17, 2026

By

TAMPA, Fla, September 17th, 2026, FinanceWire

  • Stock Locate Fees Grow More Than 20-Fold to Approximately $6.8 Million; Commissions Up Approximately 56%
  • Non-Commission Revenue Lines Now Represent Approximately 54% of Total Revenues, Up From 45% in Fiscal 2025
  • Second Consecutive Year of Positive Net Income; Cash More Than Doubles to Approximately $15.4 Million; Stockholders’ Equity of Approximately $21.1 Million
  • AtlasClearing Net Capital Up Approximately 28% Year-over-Year to $14.4 Million
  • Six New Correspondent Broker-Dealers Signed; Revenue from These Relationships Not Yet Reflected in Results
  • Growth Achieved Without At-the-Market or Equity Line Financing; No Dilutive Capital Raise Since October 2025

AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced select preliminary unaudited financial results for the fiscal year ended June 30, 2026.

Revenue

Based on preliminary unaudited results, AtlasClear expects to report fiscal 2026 total revenues of approximately $20.1 million, an increase of approximately 85% from $10.9 million in fiscal 2025. The Company also expects to report interest income of approximately $1.8 million, which is presented in other income under GAAP. Total revenues plus interest income are expected to be approximately $21.9 million, compared with approximately $12.9 million in fiscal 2025, an increase of approximately 70%. The separate audited financial statements of the Company’s broker-dealer subsidiary, AtlasClearing, Inc., for the fiscal year ended June 30, 2026, filed with the SEC on August 31, 2026, present interest income within revenues and report total revenues of approximately $21.8 million.

Growth came from both the core commission business and newer business lines. Commission revenue increased approximately 56% to approximately $9.3 million. Stock locate fees, a business the Company launched and scaled during fiscal 2026, increased to approximately $6.8 million from approximately $0.3 million and represented approximately 34% of total revenues. Net gains on firm trading accounts contributed approximately $0.5 million. As a result, commission revenue grew in absolute dollars while declining from approximately 55% of total revenues in fiscal 2025 to approximately 46% in fiscal 2026, and non-commission revenue lines represented approximately 54% of the total.

Profitability and Balance Sheet

The Company expects to report net income of approximately $2.0 million for fiscal 2026, its second consecutive year of positive net income, which includes non-cash gains from changes in the fair value of the Company’s financial instruments. At June 30, 2026, the Company expects to report cash and cash equivalents of approximately $15.4 million, more than double the $7.5 million a year earlier; total stockholders’ equity of approximately $21.1 million, compared with a stockholders’ deficit of approximately $6.8 million at June 30, 2025; and total liabilities of approximately $50.1 million, a reduction of approximately $17.6 million.

Net capital at AtlasClearing, Inc. increased to approximately $14.4 million at June 30, 2026 from $11.2 million a year earlier, as reported in AtlasClearing’s audited annual report filed with the SEC. That is approximately $14.1 million above its minimum requirement and well above the $10 million excess net capital threshold that the National Securities Clearing Corporation requires of firms that clear for introducing brokers. Net capital is stated after deducting unsecured receivables from other broker-dealers for stock locate fees, which are treated as non-allowable assets until collected and have grown with the stock locate business.

Correspondent Pipeline and Capital Discipline

AtlasClearing has signed clearing agreements with six new correspondent broker-dealers, which are in various stages of onboarding and conversion. Fiscal 2026 results include no meaningful revenue from these relationships, which the Company expects to begin contributing as conversions are completed during fiscal 2027.

Fiscal 2026 growth was achieved without reliance on at-the-market or equity line financing. The Company sold no shares under its equity line facility during fiscal 2026 and has not conducted any at-the-market offering or other dilutive capital raise since its October 2025 institutional unit financing. Shares outstanding were approximately 150.3 million at June 30, 2026 and approximately 151.8 million as of the date of this release.

Management Commentary

“Fiscal 2026 was a breakout year for AtlasClear. Revenue increased approximately 85% to roughly $20.1 million, and including interest income the business generated approximately $21.9 million,” said John Schaible, Executive Chairman of AtlasClear Holdings. “Just as important is how we got there. More than half of our revenue now comes from lines of business that barely existed two years ago, and we did it without an at-the-market program or an equity line. We finished the year with more than twice the cash, stockholders’ equity of more than $21 million, and a stronger broker-dealer. That is the foundation we intend to build on as we continue to pursue our bank strategy, and we look forward to updating shareholders in greater detail on our full-year results and operations later this month.”

“The operating story at AtlasClearing is one of execution,” said Craig Ridenhour, President of AtlasClear Holdings and Chairman of AtlasClearing, Inc. “Commissions grew more than 50%, stock locate went from a standing start to nearly $7 million, and net capital finished the year up more than $3 million. Six new correspondents have signed and none of their revenue is in these numbers yet. As those correspondents onboard, the customer assets and trading activity they bring will give us the ability to scale our stock loan business and to add new forms of interest income, including on margin balances, customer cash and securities lending, on the platform and team we already have in place, with only incremental expense.”

Preliminary Results

The preliminary financial results included in this release have been prepared by, and are the responsibility of, the Company’s management. These results are preliminary and unaudited and are subject to completion of the Company’s financial closing procedures and audit. Actual results may differ from the preliminary results presented above, and any such differences could be material. These preliminary results should not be viewed as a substitute for the Company’s full audited consolidated financial statements. Total revenues plus interest income, as used in this release, is a supplemental measure that is not calculated in accordance with GAAP. It is the sum of total revenues and interest income, each as the Company expects to report them in its consolidated statement of operations, and is presented because interest earned on balances held by the Company’s broker-dealer subsidiary is an integral part of its operating economics. It should not be considered a substitute for total revenues determined in accordance with GAAP.

Fiscal 2026 Results and Conference Call

AtlasClear expects to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and report its full fiscal 2026 financial results by September 28, 2026. The Company also expects to host a conference call to discuss its fiscal 2026 results by September 28, 2026. Additional details regarding the conference call will be provided in advance.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear Holdings seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding the Company’s preliminary unaudited financial results for the fiscal year ended June 30, 2026, expected future growth, strategic initiatives, the onboarding and conversion of the Company’s newly signed correspondent broker-dealers and the timing and revenue contribution of those relationships, the Company’s future financing activities, the expansion of the Company’s stock locate, securities lending and margin businesses, the expected timing of the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and the matters to be reported therein, the proposed acquisition of an institutional digital asset business and the proposed acquisitions of Ark Financial Services, Inc. and the Target, the anticipated timing and completion of the initial and second closings of the Dawson James transaction, the execution of definitive documentation, receipt of FINRA and other required regulatory and stockholder approvals, the anticipated growth of Dawson James’s clearing activity through AtlasClearing, the expected revenue, net income and EBITDA contributions of the proposed acquisitions, the timing of any disclosure of the Target’s identity, the Company’s intention to refile its application to acquire Commercial Bancorp of Wyoming, future financial performance, future capital markets activity, and the Company’s ability to execute on its business strategy. The letter of intent for the digital asset acquisition and the amended Dawson James letter of intent are non-binding (other than certain customary provisions), and there can be no assurance that definitive agreements will be executed or that the proposed acquisitions will be completed on the terms described, or at all.

These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the risk that the Company’s final audited results for fiscal 2026 differ from the preliminary unaudited results described in this release; AtlasClear’s failure to enter into definitive agreements with the Target or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions; AtlasClear’s inability to integrate, and to realize the benefits of, the proposed acquisitions; the risk that AtlasClear does not refile its application for the acquisition of Commercial Bancorp or that the acquisition does not close as a result of the failure to satisfy the conditions to closing such acquisition (including, without limitation, the receipt of approval of Commercial Bancorp’s stockholders and receipt of required regulatory approvals); delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; the risk that the Company does not file its Annual Report on Form 10-K within the time period anticipated; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2025, as amended, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Contacts

Jeff Ramson
jramson@pcgadvisory.com
AtlasClear Holdings, Inc
AtlasClearIR@atlasclear.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us